Chen Xin, Wei Jialin, Huang Yong, He Yi, Yang Donglin, Jiang Erlie, Ma Qiaoling, Yao Jianfeng, Zhou Lukun, Lin Xiaoting, Shen Yuyan, Yang Xin, Wang Zhao, Feng Sizhou, Han Mingzhe
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
Zhonghua Xue Ye Xue Za Zhi. 2014 Jan;35(1):9-12. doi: 10.3760/cma.j.issn.0253-2727.2014.01.003.
To evaluate the efficacy of alternative donor allogeneic hematopoietic stem cell transplantation (AD allo-HSCT) in the treatment of severe aplastic anemia (SAA).
Retrospective analysis of the clinical data of 19 SAA patients received AD allo-HSCT from May 2003 to December 2012. Of them, 12 received haploidentical HSCT (haplo-HSCT), 7 received unrelated donor transplantation. The conditioning regimen was CY+ATG+Flu±Ara-C±Bu/Mel, the GVHD preventing regimen was MMF+MTX+CSA/FK506; the median reinfusion quantity of CD34+ was 3.10(2.11-4.38)×10⁶/kg in allo-BMT and 4.90(2.08-6.88)×10⁶/kg in allo-PBSCT.
Hematopoiesis reconstitution was achieved in all 19 patients. Twelve patients developed acute graft-versus-host disease (aGVHD), and 7 developed chronic GVHD (cGVHD). Graft rejection (GR) was occurred in one patient. The median follow-up time was 13(3-115) months. Thirteen patients survived, and the prospective 5-year overall survival rate is (67.5±11.0)%.
AD allo-HSCT can be used as an alternative therapy for SAA patients without HLA matched sibling donor.
评估替代供者异基因造血干细胞移植(AD allo-HSCT)治疗重型再生障碍性贫血(SAA)的疗效。
回顾性分析2003年5月至2012年12月期间接受AD allo-HSCT的19例SAA患者的临床资料。其中,12例接受单倍体造血干细胞移植(haplo-HSCT),7例接受无关供者移植。预处理方案为CY+ATG+Flu±Ara-C±Bu/Mel,移植物抗宿主病预防方案为MMF+MTX+CSA/FK506;异基因骨髓移植(allo-BMT)中CD34+细胞的中位回输量为3.10(2.11-4.38)×10⁶/kg,异基因外周血干细胞移植(allo-PBSCT)中为4.90(2.08-6.88)×10⁶/kg。
19例患者均实现造血重建。12例患者发生急性移植物抗宿主病(aGVHD),7例发生慢性移植物抗宿主病(cGVHD)。1例患者发生移植物排斥(GR)。中位随访时间为13(3-115)个月。13例患者存活,预计5年总生存率为(67.5±11.0)%。
AD allo-HSCT可作为无HLA相合同胞供者的SAA患者的替代治疗方法。